Inovio Pharmaceuticals
Stock Forecast, Prediction & Price Target
Inovio Pharmaceuticals Financial Estimates
Inovio Pharmaceuticals Revenue Estimates
Inovio Pharmaceuticals EBITDA Estimates
Inovio Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $1.77M N/A | $10.26M 478.23% | $832.01K -91.89% | Avg: $19.80M Low: $7.16M High: $32.44M avg. 2280.46% | Avg: $78.06M Low: $28.28M High: $127.83M avg. 294.15% | Avg: $233.67M Low: $84.66M High: $382.63M avg. 199.32% | Avg: $428.25M Low: $155.16M High: $701.24M avg. 83.26% |
Net Income
% change YoY
| $-305.38M N/A | $-287.66M 5.80% | $-135.11M 53.02% | Avg: $-108.37M Low: $-89.58M High: $-38.80M avg. 19.79% | Avg: $-60.62M Low: $-68.96M High: $17.73M avg. 44.05% | Avg: $36.29M Low: $6.20M High: $66.36M avg. 159.86% | Avg: $127.27M Low: $21.76M High: $232.75M avg. 250.71% |
EBITDA
% change YoY
| $-293.33M N/A | $-268.55M 8.44% | $-130.39M 51.44% | Avg: $-19.80M Low: $-32.44M High: $-7.16M avg. 84.81% | Avg: $-78.06M Low: $-127.83M High: $-28.28M avg. -294.15% | Avg: $-233.67M Low: $-382.63M High: $-84.66M avg. -199.32% | Avg: $-428.25M Low: $-701.24M High: $-155.16M avg. -83.26% |
EPS
% change YoY
| -$17.55 N/A | -$14.47 17.54% | -$6.09 57.91% | Avg: -$3.19 Low: -$4.04 High: -$1.75 avg. 47.67% | Avg: -$1.5 Low: -$3.11 High: $0.8 avg. 53.08% | Avg: $1.64 Low: $0.28 High: $2.99 avg. 209.47% | Avg: $5.74 Low: $0.98 High: $10.5 avg. 250.71% |
Operating Expenses
% change YoY
| $302.99M N/A | $277.83M -8.30% | $132.55M -52.29% | Avg: $410.75M Low: $148.55M High: $672.95M avg. 209.87% | Avg: $1.61B Low: $586.59M High: $2.65B avg. 294.15% | Avg: $4.84B Low: $1.75B High: $7.93B avg. 199.32% | Avg: $8.88B Low: $3.21B High: $14.54B avg. 83.26% |
FAQ
What is Inovio Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 118.60% in 2025-2028.
We have gathered data from 5 analysts. Their low estimate is -89.58M, average is -108.37M and high is -38.80M.
What is Inovio Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 714.30% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $7.16M, average is $19.80M and high is $32.44M.
What is Inovio Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 140.23% in 2025-2028.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$4.04, average is -$3.19 and high is $-1.75.
What is the best performing analyst?
In the last twelve months analysts have been covering Inovio Pharmaceuticals stock. The most successful analyst is Hartaj Singh whose win rate is 50%. He has correctly predicted 1/2 price targets.